Caring ALS Member since
Average Response Time
I am a neurologist with over 25 years of experience. Having completed both my neurology and psychiatry residency at Long Island Jewish Medical Center, I currently treat patients with neurodegenerative diseases like ALS, Parkinson’s, Alzheimer’s, and MS at my private practice in Tarrytown, New York. My current research is in identifying specific metabolic factors that precipitate neurodegeneration in hopes of advancing the connection between a dysregulated immune system and neurodegenerative disorders, which is often referred to as a state of “immune exhaustion�? and chronic infectious disease. I also focus on research regarding the mitochondria in Autism, gene therapy in Batten’s disease, and antisense technologies in pediatric brain cancer. I have a strong sense of optimism and my efforts are dedicated to aligning with my patients in fighting against ALS by utilizing my philosophy of taking an integrative approach of pharmaceutical, non-pharmaceutical, and near-infrared light therapy approaches to address both the physical and existential-emotional issues that play a key role in prognosis.
MD, Nova Southeastern University
What makes me unique
Photobiomodulation (PBM) also known as low-level laser (or light) therapy (LLLT), has been known for almost 50 years but still has not gained widespread acceptance.
Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease
Alzheimer's and Parkinson's disease are the two most common neurodegenerative disorders. They develop after a progressive death of many neurons in the brain. Although therapies are available to treat the signs and symptoms of both diseases, the progression of neuronal death remains relentless, and it has proved difficult to slow or stop.
Low-level laser (light) therapy (LLLT) involves absorption of photons being in the mitochondria of cells leading to improvement in electron transport, increased mitochondrial membrane potential (MMP), and greater ATP production.
Low-Level Laser Therapy Rescues Dendrite Atrophy via Upregulating BDNF Expression: Implications for Alzheimer's Disease
Downregulation of brain-derived neurotrophic factor (BDNF) in the hippocampus occurs early in the progression of Alzheimer's disease (AD). Since BDNF plays a critical role in neuronal survival and dendrite growth.
Low-Level laser therapy for traumatic brain injury in mice increases brain derived neurotrophic factor (BDNF) and synaptogenesis
Transcranial low�?level laser (light) therapy (LLLT) is a new non�?invasive approach to treating a range of brain disorders including traumatic brain injury (TBI). We (and others) have shown that applying near�?infrared light to the head of animals that have suffered TBI produces improvement in neurological functioning.
1 hour consult
DR. Jay Lombard
Remote (Video) Consultation – Access Anywhere: 1 x 60-minute Initial Consult. Discuss which ALS treatment is right for you.
PRICED AT $500
3 hour evaluation
DR. Jay Lombard
Remote (Video) Consultation – Access Anywhere: 180-minute evaluation. Review prior records.
PRICED AT $1,000
3 month package
DR. Jay Lombard
Remote (Video) Consultation – Access Anywhere: 3 month care package. Work with you intensely to help slow progression of the disease
PRICED AT $3,000